Literature DB >> 18998214

Sentinel lymph node biopsy in melanoma.

Matthew T Hueman1, Julie R Lange.   

Abstract

Sentinel lymph node biopsy (SLNB) for patients with newly diagnosed localized invasive melanoma provides excellent prognostic information and results in improved regional disease control. Prior to the common use of SLNB, regional nodal recurrence was the single most common site of melanoma recurrence, with symptomatic, bulky disease that could be disabling and difficult or impossible to control. With the widespread use of SLNB, regional recurrence of melanoma is much less frequent. Even without clear evidence of improvement in overall survival, the significant and reliable prognostic information and the improved regional control make sentinel node biopsy an important procedure that should be offered routinely to many patients with newly diagnosed melanoma.

Entities:  

Mesh:

Year:  2008        PMID: 18998214     DOI: 10.1007/s11864-008-0074-0

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  27 in total

1.  HMB-45 immunohistochemical staining of sentinel lymph nodes: a specific method for enhancing detection of micrometastases in patients with melanoma.

Authors:  B L Baisden; F B Askin; J R Lange; W H Westra
Journal:  Am J Surg Pathol       Date:  2000-08       Impact factor: 6.394

2.  Patterns of early recurrence after sentinel lymph node biopsy for melanoma.

Authors:  Celia Chao; Sandra L Wong; Merrick I Ross; Douglas S Reintgen; R Dirk Noyes; Patricia B Cerrito; Michael J Edwards; Kelly M McMasters
Journal:  Am J Surg       Date:  2002-12       Impact factor: 2.565

3.  The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.

Authors:  M G Statius Muller; P A van Leeuwen; E S de Lange-De Klerk; P J van Diest; R Pijpers; C C Ferwerda; R J Vuylsteke; S Meijer
Journal:  Cancer       Date:  2001-06-15       Impact factor: 6.860

4.  Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes.

Authors:  J F Thompson; W H McCarthy; C M Bosch; C J O'Brien; M J Quinn; S Paramaesvaran; K Crotty; S W McCarthy; R F Uren; R Howman-Giles
Journal:  Melanoma Res       Date:  1995-08       Impact factor: 3.599

5.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Authors:  C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

6.  Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study.

Authors:  Sandra L Wong; Donald L Morton; John F Thompson; Jeffrey E Gershenwald; Stanley P L Leong; Douglas S Reintgen; Haim Gutman; Michael S Sabel; Grant W Carlson; Kelly M McMasters; Douglas S Tyler; James S Goydos; Alexander M M Eggermont; Omgo E Nieweg; A Benedict Cosimi; Adam I Riker; Daniel G Coit
Journal:  Ann Surg Oncol       Date:  2006-04-12       Impact factor: 5.344

7.  Sentinel-node biopsy or nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Robert Elashoff; Richard Essner; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; Edwin C Glass; He-Jing Wang
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

8.  Gamma-probe-guided lymph node localization in malignant melanoma.

Authors:  J C Alex; D L Weaver; J T Fairbank; B S Rankin; D N Krag
Journal:  Surg Oncol       Date:  1993-10       Impact factor: 3.279

9.  Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma.

Authors:  Randall P Scheri; Richard Essner; Roderick R Turner; Xing Ye; Donald L Morton
Journal:  Ann Surg Oncol       Date:  2007-07-18       Impact factor: 5.344

10.  Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients.

Authors:  Dennis L Rousseau; Merrick I Ross; Marcella M Johnson; Victor G Prieto; Jeffrey E Lee; Paul F Mansfield; Jeffrey E Gershenwald
Journal:  Ann Surg Oncol       Date:  2003-06       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.